
CLAIMS

1. A compound represented by the formula:



Formula **Ib**

a tautomer thereof, a deuterated derivative of that compound or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

Ring A is chosen from C_6 aryl and 5- and 6-membered heteroaryl groups;

R^1, for each occurrence, is independently chosen from halogen, -OH, =O, cyano, phenyl, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_3-C_6 carbocyclyl, 4- to 6-membered heterocyclyl, -C(=O)N(**R^c**)$_2$, and -SO_2(**R^c**) groups, wherein:

R^c, for each occurrence, is independently chosen from hydrogen and C_1-C_4 alkyl groups;

the 4- to 6-membered heterocyclyl of **R^1** comprises one heteroatom chosen from nitrogen and oxygen;

the C_1-C_6 alkyl of **R^1** is optionally substituted with 1 to 3 groups independently chosen from halogen, cyano, -OH, -NH_2, -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, and C_1-C_4 alkoxy groups;

the C_1-C_6 alkoxy of **R^1** is optionally substituted with 1 to 3 groups independently chosen from -OH, cyano, and halogen groups;

the C_3-C_6 carbocyclyl of **R^1** is optionally substituted with 1 to 3 groups independently chosen from halogen, cyano, -OH, -NH_2, -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, C_1-C_4 alkyl, C_1-C_4 alkoxy, -C(=O)NH_2, -C(=O)NH(C_1-C_4 alkyl), and -C(=O)N(C_1-C_4 alkyl)$_2$ groups; and


the phenyl of **R^1** is optionally substituted with 1 to 3 groups independently chosen from halogen, cyano, -OH, -NH_2, -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, C_1-

C_4 alkyl, C_1-C_4 alkoxy, -C(=O)NH_2, -C(=O)NH(C_1-C_4 alkyl), and -C(=O)N(C_1-C_4 alkyl)$_2$ groups; or

wherein two **R^1** groups taken together with the **Ring A** atoms connecting them form a 5- to 6-membered cycloalkyl, 5- to 8-membered heterocyclyl, 5- to 6-membered aryl, or 5- to 6-membered heteroaryl ring,

wherein the 5- to 6-membered cycloalkyl, 5- to 8-membered heterocyclyl, 5- to 6-membered aryl, 5- to 6-membered heteroaryl are each optionally substituted with 1 to 4 groups chosen from halogen, -OH, and C_1-C_4 alkyl;

R^2 is chosen from C_1-C_6 alkyl, -C(=O)O(C_1-C_4 alkyl), C_2-C_6 alkynyl, and



, wherein:

the C_1-C_6 alkyl of **R^2** is substituted with 1 to 3 groups independently chosen from halogen, cyano, -OH, -NH_2, -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, C_1-C_4 alkoxy, -C(=O)NH_2, -C(=O)NH(C_1-C_4 alkyl), -C(=O)N(C_1-C_4 alkyl)$_2$, C_3-C_6 carbocyclyl, 5- to 10-membered heterocyclyl, C_6 aryl, and 5- to 10-membered heteroaryl groups;

Ring B is chosen from C_3-C_{12} carbocyclyl, 3- to 12-membered heterocyclyl, C_6 and C_{10} aryl, and 5- to 10-membered heteroaryl groups, wherein **Ring B** is optionally substituted with 1, 2, 3, 4, or 5 **R^a** groups; wherein:

R^a, for each occurrence, is independently chosen from halogen, cyano, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_1-C_6 alkoxy, C_1-C_6 haloalkyl, C_1-C_6 haloalkenyl, C_1-C_6 haloalkoxy, -C(=O)N**R^h****R^i**, -N**R^h****R^i**, -N**R^h**C(=O)**R^k**, -N**R^h**C(=O)O**R^k**, -N**R^h**C(=O)N**R^i****R^j**, -N**R^h**S(=O)$_p$**R^k**, -O**R^k**, -OC(=O)**R^k**, -OC(=O)O**R^k**, -OC(=O)N**R^h****R^i**, -[O(CH_2)$_q$]$_r$O(C_1-C_6 alkyl), -S(=O)$_p$**R^k**, -S(=O)$_p$N**R^h****R^i**, -C(=O)O**R^k**, C_3-C_{12} carbocyclyl, 3- to 12-membered heterocyclyl, C_6 and C_{10} aryl, and 5- to 10-membered heteroaryl groups, wherein:

the C_1-C_6 alkyl, C_1-C_6 alkoxy, and the C_2-C_6 alkenyl of **R^a** are each optionally substituted with 1 to 3 groups independently chosen from C_6 to C_{10} aryl (optionally substituted with 1 to 3 **R^m** groups), 5- to 10-membered heterocyclyl (optionally substituted

with 1 to 3 $\mathbf{R^m}$ groups), 5- to 10-membered heteroaryl (optionally substituted with 1 to 3 $\mathbf{R^m}$ groups), cyano, -C(=O)$\mathbf{R^k}$, -C(=O)O$\mathbf{R^k}$, -C(=O)N$\mathbf{R^h R^i}$, -N$\mathbf{R^h R^i}$, -N$\mathbf{R^h}$C(=O)$\mathbf{R^k}$, -N$\mathbf{R^h}$C(=O)O$\mathbf{R^k}$, -N$\mathbf{R^h}$C(=O)N$\mathbf{R^i R^j}$, -N$\mathbf{R^h}$S(=O)$_\mathbf{p}\mathbf{R^k}$, -O$\mathbf{R^k}$, -OC(=O)$\mathbf{R^k}$, -OC(=O)O$\mathbf{R^k}$, -OC(=O)N$\mathbf{R^h R^i}$, -S(=O)$_\mathbf{p}\mathbf{R^k}$, -S(=O)$_\mathbf{p}$N$\mathbf{R^h R^i}$, -O(C_6 aryl) (optionally substituted with 1 to 3 $\mathbf{R^m}$ groups), and C_3-C_6 carbocyclyl groups (optionally substituted with 1 to 3 $\mathbf{R^m}$ groups);

the C_3-C_{12} carbocyclyl, the 3- to 12-membered heterocyclyl, the C_6 and C_{10} aryl, and the 5- to 10-membered heteroaryl of $\mathbf{R^a}$ are each optionally substituted with 1 to 3 groups independently chosen from halogen, cyano, C_1-C_4 alkyl, -N$\mathbf{R^h R^i}$, and -O$\mathbf{R^k}$ groups, wherein:

$\mathbf{R^h}$, $\mathbf{R^i}$, and $\mathbf{R^j}$, for each occurrence, are each independently chosen from hydrogen, C_1-C_4 alkyl, C_6-C_{10} aryl, and C_3-C_6 cycloalkyl groups, wherein:

the C_1-C_4 alkyl of any one of $\mathbf{R^h}$, $\mathbf{R^i}$, and $\mathbf{R^j}$ is optionally substituted with 1 to 3 groups independently chosen from halogen, cyano, and -OH groups;

$\mathbf{R^k}$, for each occurrence, is independently chosen from hydrogen, C_1-C_4 alkyl, 5- to 10-membered heterocyclyl, and C_3-C_6 carbocyclyl groups, wherein:

the C_1-C_4 alkyl of any one of $\mathbf{R^k}$ is optionally substituted with 1 to 3 groups independently chosen from halogen, cyano, and -OH groups;

$\mathbf{R^m}$, for each occurrence, is independently chosen from halogen, cyano, oxo, C_1-C_6 alkyl, C_1-C_6 alkoxy, -S(=O)$_\mathbf{p}\mathbf{R^k}$, and -O$\mathbf{R^k}$ groups, wherein:

the C_1-C_6 alkyl of $\mathbf{R^m}$ is optionally substituted with 1 to 3 groups independently chosen from halogen, cyano, -OH, and -O(C_1-C_4 alkyl) groups;

$\mathbf{R^3}$ is chosen from C_1-C_6 alkyl, C_3-C_{12} carbocyclyl, 3- to 12-membered heterocyclyl, and 5- to 10-membered heteroaryl groups, wherein:

the C_1-C_6 alkyl of $\mathbf{R^3}$ is optionally substituted with 1 to 3 groups independently chosen from halogen, cyano, -OH, -NH_2, -NH(C_1-C_4 alkyl), -N(C_1-

C_4 alkyl)$_2$, C_1-C_4 alkoxy, -C(=O)NH_2, -C(=O)NH(C_1-C_4 alkyl), and -C(=O)N(C_1-C_4 alkyl)$_2$ groups;

the C_3-C_{12} carbocyclyl, the 3- to 12-membered heterocyclyl, and the 5- to 10-membered heteroaryl of **R^3** are each optionally substituted with 1 to 3 groups independently chosen from halogen, cyano, -OH, -NH_2, -NH(C_1-C_4 alkyl) (optionally substituted with -OH), -N(C_1-C_4 alkyl)$_2$, C_1-C_5 alkyl (optionally substituted with -OH or -S(=O)$_2$(C_1-C_4 alkyl)), C_1-C_4 alkoxy, -C(=O)NH_2, -C(=O)NH(C_1-C_4 alkyl), -NHC(=O)(C_1-C_4 alkyl), -C(=O)(C_1-C_4 alkoxy), and -C(=O)N(C_1-C_4 alkyl)$_2$ groups;

R^4 is chosen from halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, -$(CH_2)_n$C(=O)N**$R^n$$R^o$**, -N**$R^n$$R^o$**, -N**$R^o$**C(=O)**$R^p$**, -N**$R^n$**S(=O)$_p$**$R^p$**, -$(CH_2)_n$O**$R^p$**, -S(=O)$_p$**$R^p$**, and -$(CH_2)_n$C(=O)O**$R^p$** groups, wherein:

R^n and **R^o**, for each occurrence, are each independently chosen from hydrogen and C_1-C_4 alkyl groups; and

R^p, for each occurrence, is independently chosen from hydrogen, C_1-C_4 alkyl, and C_1-C_4 haloalkyl groups;

m is an integer chosen from 0, 1, 2, 3, 4, and 5;

n is an integer chosen from 0, 1, and 2;

p, for each occurrence, is an integer independently chosen from 1 and 2; and


q and **r**, for each occurrence, are each an integer independently chosen from 1, 2, 3, and 4.

2. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1, wherein **R^4** is -OH.


3. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1, wherein **R^3** is chosen from C_1-C_4 alkyl groups.

4. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1, wherein **R^3** is -CH_3.

5. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1, wherein the compound is represented by one of the following structural formulae:

















Formula **Ic-4**




Formula **II-4**

a tautomer thereof, a deuterated derivative of that compound or tautomer, or a pharmaceutically acceptable salt of any of the foregoing.

6. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1, wherein **Ring B** is chosen from , , , , .


,

,

,

,

,

,

,

,

, and

; each of which is optionally substituted with 1, 2, 3, 4, or 5 **R^{a}** groups.

7. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1, wherein **Ring B** is

which is optionally substituted with 1 **R^{a}** group.

8. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1, wherein **R^{1}**, for each occurrence, is independently chosen from F, Cl, Br, -CH_3, -$CH(CH_3)_2$, -CF_3, -OCH_3, -OCF_3, -$C(=O)N(CH_3)_2$, and cyclopropyl.


9. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1, wherein **m** is 1.

10. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1, wherein **m** is 2.


11. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1, wherein **R^{a}**, for each occurrence, is independently chosen from -CH_3 and -$(CH_2)_2SO_2CH_3$.

12. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1, wherein **Ring A** is phenyl.


13. A compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from the compounds




1




2




3




4




5




6




7




8




9




10




11




12




13




14




15




16




17




18




19




20




21




22




23




24




25




26




27




28




29




I5




I6




I7




I8




I9




I10




I11




I12




I13




I14




I15




I16




I17




I18




I19




I20




I21




I22




I23




I24




I25




I26




I27




I28




I29




I30




I31




I32




I33




I34




I35




I36




I37




I38




I39




I40




I41




I42




I43




I44





I45





I46



I47



I48



I49



I50



I51



I52



I53



I54



I55



I56



I57


I58



I59


I60



I61




I62




I63




I64




I65




I66




I67




I68




I69




I70




I71




I72




I73




I74




I75




I76




I77




I78




I79




I80




I81




I82




I83




I84




I85




I86




I87




I88




I89




I90




I91




I92




I93




I94




I95




I96




I97




I98




I99




I100




I101




I102




I103




I104




I105




I106




I107




I108




I109




I110




I111




I112




I113




I114




I115




I116




I117




I118




I119




I120




I121




I122




I123




I124




I125




I126




I127




I128




I129




I130




I131




I132




I133




I134




I135




I136




I137




I138




I139




I140




I141




I142




I143




I144




I145




I146




I147




I148




I149




I150




I151




I152




I153




I154




I155




I156




I157




I158




I159




I160




I161




I162




I163




I164




I165




I166




I167




I168




I169




I170




I171




I172




I173




I174




I175




I176




I177




I178




I179




I180




I181




I182




I183




I184




I185




I186




I187




I188




I189




I190




I191




I192




I193




I194




I195




I196




I197




I198




I199




I200




I201




I202




I203




I204




I205




I206




I207




I208




I209




I210




I211




I212




I213




I214




I215




I216




I217




I218




I219




I220




I221




I222




I223




I224




I225




I226




I227




I228




I229




I230




I231




I232




I233




I234




I235




I236




I237




I238




I239




I240




I241




I242




I243




I244




I245




I246




I247




I248




I249




I250




I251




I252




I253




I254




I255




I256




I257




I258




I259




I260




I261




I262




I263




I264




I265




I266




I267




I268




I269




I270




I271




I272




I273




I274




I275




I276




I277




I278




I279




I280




I281




I282




I283




I284




I285




I286




I287




I288




I289




I290




I291




I292




I293




I294




I295




30




31




32




33




34




35




36




37




38




39




40




41




42




43




44




I296




45




46




47




48




49




50




51




52




53




54




55




56




57




58



59




60



,

tautomers thereof, deuterated derivatives of those compounds and tautomers, and pharmaceutically acceptable salts of any of the foregoing.


14. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt of claim 13, wherein the compound is Compound 16:



(Compound 16)


or a pharmaceutically acceptable salt thereof.

15. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt of claim 13, wherein the compound is Compound 16:



(Compound 16).

16. A compound represented by the formula:




Formula **II-6a**

a tautomer thereof, a deuterated derivative of that compound or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

R^{1a} and **R^{1b}** are independently chosen from halogen, H, C_1-C_4 alkyl, and C_1-C_4 haloalkyl groups;

R^{1c} is chosen from halogen, H, CH_3, -OH, and -CH_2OH; and

R^2 is chosen from C_1-C_6 alkyl, -C(=O)O(C_1-C_4 alkyl), C_2-C_6 alkynyl, and



, wherein:

the C_1-C_6 alkyl of **R^2** is substituted with 1 to 3 groups independently chosen from halogen, cyano, -OH, -NH_2, -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, C_1-C_4 alkoxy, -C(=O)NH_2, -C(=O)NH(C_1-C_4 alkyl), -C(=O)N(C_1-C_4 alkyl)$_2$, C_3-C_6 carbocyclyl, 5- to 10-membered heterocyclyl, C_6 aryl, and 5- to 10-membered heteroaryl groups;

Ring B is chosen from C_3-C_{12} carbocyclyl, 3- to 12-membered heterocyclyl, C_6 and C_{10} aryl, and 5- to 10-membered heteroaryl groups, wherein **Ring B** is optionally substituted with 1, 2, 3, 4, or 5 $\mathbf{R^a}$ groups; wherein:

$\mathbf{R^a}$, for each occurrence, is independently chosen from halogen, cyano, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_1-C_6 alkoxy, C_1-C_6 haloalkyl, C_1-C_6 haloalkenyl, C_1-C_6 haloalkoxy, -C(=O)N$\mathbf{R^h}\mathbf{R^i}$, -N$\mathbf{R^h}\mathbf{R^i}$, -N$\mathbf{R^h}$C(=O)$\mathbf{R^k}$, -N$\mathbf{R^h}$C(=O)O$\mathbf{R^k}$, -N$\mathbf{R^h}$C(=O)N$\mathbf{R^i}\mathbf{R^j}$, -N$\mathbf{R^h}$S(=O)$_\mathbf{p}\mathbf{R^k}$, -O$\mathbf{R^k}$, -OC(=O)$\mathbf{R^k}$, -OC(=O)O$\mathbf{R^k}$, -OC(=O)N$\mathbf{R^h}\mathbf{R^i}$, -[O(CH_2)$_\mathbf{q}$]$_\mathbf{r}$O(C_1-C_6 alkyl), -S(=O)$_\mathbf{p}\mathbf{R^k}$, -S(=O)$_\mathbf{p}$N$\mathbf{R^h}\mathbf{R^i}$, -C(=O)O$\mathbf{R^k}$, C_3-C_{12} carbocyclyl, 3- to 12-membered heterocyclyl, C_6 and C_{10} aryl, and 5- to 10-membered heteroaryl groups, wherein:

the C_1-C_6 alkyl, C_1-C_6 alkoxy, and the C_2-C_6 alkenyl of $\mathbf{R^a}$ are each optionally substituted with 1 to 3 groups independently chosen from C_6 to C_{10} aryl (optionally substituted with 1 to 3 $\mathbf{R^m}$ groups), 5- to 10-membered heterocyclyl (optionally substituted with 1 to 3 $\mathbf{R^m}$ groups), 5- to 10-membered heteroaryl (optionally substituted with 1 to 3 $\mathbf{R^m}$ groups), cyano, -C(=O)$\mathbf{R^k}$, -C(=O)O$\mathbf{R^k}$, -C(=O)N$\mathbf{R^h}\mathbf{R^i}$, -N$\mathbf{R^h}\mathbf{R^i}$, -N$\mathbf{R^h}$C(=O)$\mathbf{R^k}$, -N$\mathbf{R^h}$C(=O)O$\mathbf{R^k}$, -N$\mathbf{R^h}$C(=O)N$\mathbf{R^i}\mathbf{R^j}$, -N$\mathbf{R^h}$S(=O)$_\mathbf{p}\mathbf{R^k}$, -O$\mathbf{R^k}$, -OC(=O)$\mathbf{R^k}$, -OC(=O)O$\mathbf{R^k}$, -OC(=O)N$\mathbf{R^h}\mathbf{R^i}$, -S(=O)$_\mathbf{p}\mathbf{R^k}$, -S(=O)$_\mathbf{p}$N$\mathbf{R^h}\mathbf{R^i}$, -O(C_6 aryl) (optionally substituted with 1 to 3 $\mathbf{R^m}$ groups), and C_3-C_6 carbocyclyl groups (optionally substituted with 1 to 3 $\mathbf{R^m}$ groups);

the C_3-C_{12} carbocyclyl, the 3- to 12-membered heterocyclyl, the C_6 and C_{10} aryl, and the 5- to 10-membered heteroaryl of $\mathbf{R^a}$ are each optionally substituted with 1 to 3 groups independently chosen from halogen, cyano, C_1-C_4 alkyl, -N$\mathbf{R^h}\mathbf{R^i}$, and -O$\mathbf{R^k}$ groups, wherein:

$\mathbf{R^h}$, $\mathbf{R^i}$, and $\mathbf{R^j}$, for each occurrence, are each independently chosen from hydrogen, C_1-C_4 alkyl, C_6-C_{10} aryl, and C_3-C_6 cycloalkyl groups, wherein:

the C_1-C_4 alkyl of any one of $\mathbf{R^h}$, $\mathbf{R^i}$, and $\mathbf{R^j}$ is optionally substituted with 1 to 3 groups independently chosen from halogen, cyano, and -OH groups;


R^k, for each occurrence, is independently chosen from hydrogen, C_1-C_4 alkyl, 5- to 10-membered heterocyclyl, and C_3-C_6 carbocyclyl groups, wherein:

the C_1-C_4 alkyl of any one of **R^k** is optionally substituted with 1 to 3 groups independently chosen from halogen, cyano, and -OH groups;

R^m, for each occurrence, is independently chosen from halogen, cyano, oxo, C_1-C_6 alkyl, C_1-C_6 alkoxy, -S(=O)$_p$**R^k**, and -O**R^k** groups, wherein:

the C_1-C_6 alkyl of **R^m** is optionally substituted with 1 to 3 groups independently chosen from halogen, cyano, -OH, and -O(C_1-C_4 alkyl) groups.

17. A compound represented by the formula:



Formula **II-6b**

a tautomer thereof, a deuterated derivative of that compound or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

R^{1a} and **R^{1b}** are independently chosen from halogen, H, C_1-C_4 alkyl, and C_1-C_4 haloalkyl groups; and

R^{1c} is chosen from halogen, H, CH_3, -OH, and -CH_2OH.

18. A silicon, boron, or phosphorous derivative of the at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 17.

19. A pharmaceutical composition comprising at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 17 and a pharmaceutically acceptable carrier.

20. Use of the compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 17 in the manufacture of a medicament for the treatment of focal segmental glomerulosclerosis and/or non-diabetic kidney disease.

21. Use of the compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 17 in the manufacture of a medicament for the treatment of an APOL1-mediated disease.

22. The use according to claim 21, wherein the APOL1-mediated disease is cancer.